ArticleThe Journal of international medical research2025
The histone deacetylase inhibitor CG-745 enhances the radiosensitivity of prostate cancer cells.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo investigate the possible correlation between histone deacetylase inhibition and radiosensitivity in PC-3 prostate cancer cells and to explore the possible mechanism involved.MethodsPC-3 prostate cancer cells were treated with 0.40 μM CG-745 alone, radiation alone, or 0.40 μM CG-745 in combination with radiation. A CCK-8 kit was used to measure the proliferation of PC-3 cells. The colony formation assay was used to determine cell reproductive survival. Immunofluorescence analysis was used to detect the location of phosphorylated H2AX foci. Apoptosis and cell cycle distribution of PC-3 cells were assessed via flow cytometry analysis.ResultsCG-745 enhances the repressive effect of irradiation on PC-3 cell growth, as shown by the CCK-8 assay and colony formation assay. Compared with CG-745 or radiation alone, CG-745 combined with radiation significantly increased phosphorylated H2AX foci formation. The combination of CG-745 and radiation significantly increased the percentage of cells in the S phase and decreased percentage of cells in the G2 and G1 phases compared with treatment with CG-745 alone or radiation alone. Flow cytometry analysis showed that CG-745 promoted the PC-3 cell apoptosis induced by radiation.ConclusionsThe histone deacetylase inhibitor CG-745 enhanced radiation-induced DNA damage, cell cycle arrest, and cell apoptosis, thus increasing the radiosensitivity of PC-3 prostate cancer cells to X-ray irradiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.